Richard L Boyd
Overview
Explore the profile of Richard L Boyd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
3133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evtimov V, Hammett M, Pupovac A, Nguyen N, Shu R, Van Der Weyden C, et al.
Heliyon
. 2024 Sep;
10(17):e36298.
PMID: 39263154
Purpose: Current monoclonal antibody-based treatment approaches for cutaneous T cell lymphoma (CTCL) rely heavily on the ability to identify a tumor specific target that is essentially absent on normal cells....
2.
DRozario J, Knoblich K, Lutge M, Shibayama C, Cheng H, Alexandre Y, et al.
Eur J Immunol
. 2023 Mar;
53(9):e2250355.
PMID: 36991561
The lymph node (LN) is home to resident macrophage populations that are essential for immune function and homeostasis, but key factors controlling this niche are undefined. Here, we show that...
3.
To V, Evtimov V, Jenkin G, Pupovac A, Trounson A, Boyd R
Front Immunol
. 2022 Sep;
13:968395.
PMID: 36059451
Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited. Barriers...
4.
Suraiya A, Evtimov V, Truong V, Boyd R, Forsythe J, Boyd N
Transl Oncol
. 2022 Jul;
24:101477.
PMID: 35905640
Chimeric antigen receptor (CAR-) T cells are revolutionizing cancer treatment, as a direct result of their clinical impact on the treatment of hematological malignancies. However for solid tumors, CAR-T cell...
5.
Shu R, Evtimov V, Hammett M, Nguyen N, Zhuang J, Hudson P, et al.
Mol Ther Oncolytics
. 2021 Feb;
20:325-341.
PMID: 33614914
Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies...
6.
Shi Y, Truong V, Kulkarni K, Qu Y, Simon G, Boyd R, et al.
J Mater Chem B
. 2020 Apr;
3(45):8771-8774.
PMID: 32263472
Light triggered release of an antibiotic from a click crosslinked hydrogel was developed by conjugating ciprofloxacin through a photo-cleavable linker to the hydrogel network structure. Upon irradiation of the hydrogel...
7.
Trounson A, Boyd N, Boyd R
Cell Stem Cell
. 2019 Apr;
24(4):508-510.
PMID: 30951658
In this issue of Cell Stem Cell, Xu et al. (2019) demonstrate that editing iPSCs' major histocompatibility antigens may potentially provide a small set of universally compatible stem cell lines...
8.
Wiede F, Dudakov J, Lu K, Dodd G, Butt T, Godfrey D, et al.
J Exp Med
. 2017 Aug;
214(9):2733-2758.
PMID: 28798028
In the thymus, hematopoietic progenitors commit to the T cell lineage and undergo sequential differentiation to generate diverse T cell subsets, including major histocompatibility complex (MHC)-restricted αβ T cell receptor...
9.
Dudakov J, Mertelsmann A, OConnor M, Jenq R, Velardi E, Young L, et al.
Blood
. 2017 Jun;
130(7):933-942.
PMID: 28607133
Graft-versus-host disease (GVHD) and posttransplant immunodeficiency are frequently related complications of allogeneic hematopoietic transplantation. Alloreactive donor T cells can damage thymic epithelium, thus limiting new T-cell development. Although the thymus...
10.
Barsanti M, Lim J, Hun M, Lister N, Wong K, Hammett M, et al.
Eur J Immunol
. 2016 Nov;
47(2):291-304.
PMID: 27861793
Although forkhead-box n1 (Foxn1) is a critical thymic epithelial cell regulator in thymus organogenesis, its association with epithelial differentiation and homeostasis in the postnatal and aged thymic microenvironment remains conflicting....